Brain of miyoshi myopathy/dysferlinopathy patients presents with structural and metabolic anomalies.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 08 2024
Historique:
received: 06 02 2024
accepted: 12 08 2024
medline: 21 8 2024
pubmed: 21 8 2024
entrez: 20 8 2024
Statut: epublish

Résumé

Miyoshi myopathy/dysferlinopathy (MMD) is a rare muscle disease caused by DYSF gene mutations. Apart from skeletal muscles, DYSF is also expressed in the brain. However, the impact of MMD-causing DYSF variants on brain structure and function remains unexplored. To investigate this, we utilized magnetic resonance (MR) modalities (MR volumetry and

Identifiants

pubmed: 39164335
doi: 10.1038/s41598-024-69966-4
pii: 10.1038/s41598-024-69966-4
doi:

Substances chimiques

Magnesium I38ZP9992A
Dysferlin 0
DYSF protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19267

Subventions

Organisme : Agentúra na Podporu Výskumu a Vývoja
ID : APVV-SK-AT-20-0010
Organisme : Agentúra na Podporu Výskumu a Vývoja
ID : APVV-19-0222
Organisme : Austrian Federal Ministry of Education, Science and Research
ID : WTZ Mobility SK11-2021

Informations de copyright

© 2024. The Author(s).

Références

Miyoshi, K. et al. Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy. Seventeen cases in eight families including an autopsied case. Brain. 109, 31–54. https://doi.org/10.1093/brain/109.1.31 (1986).
doi: 10.1093/brain/109.1.31 pubmed: 3942856
Takahashi, T. et al. Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B. J. Neurol. Neurosurg. Psychiatry. 84, 433–40. https://doi.org/10.1136/jnnp-2011-301339 (2013).
doi: 10.1136/jnnp-2011-301339 pubmed: 23243261
Zhang, H. et al. Abnormal expression of dysferlin in blood monocytes supports primary dysferlinopathy in patients confirmed by genetic analyses. Front. Neurol. 11, 540098. https://doi.org/10.3389/fneur.2020.540098 (2020).
doi: 10.3389/fneur.2020.540098 pubmed: 33613410
Bejaoui, K. et al. Genetic fine mapping of the Miyoshi myopathy locus and exclusion of eight candidate genes. Neurogenetics. 1, 189–96. https://doi.org/10.1007/s100480050028 (1998).
doi: 10.1007/s100480050028 pubmed: 10737122
Bushby, K. & Straub, V. One gene, one or many diseases? Simplifying dysferlinopathy. Neurology. 75, 298–9. https://doi.org/10.1212/WNL.0b013e3181ea1649 (2010).
doi: 10.1212/WNL.0b013e3181ea1649 pubmed: 20574035
Liu, J. et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 20, 31–6. https://doi.org/10.1038/1682 (1998).
doi: 10.1038/1682 pubmed: 9731526
Takahashi, T. et al. Dysferlin mutations in Japanese Miyoshi myopathy: Relationship to phenotype. Neurology. 60, 1799–804. https://doi.org/10.1212/01.wnl.0000068333.43005.12 (2003).
doi: 10.1212/01.wnl.0000068333.43005.12 pubmed: 12796534
MedlinePlus. Available from: https://medlineplus.gov/ .
Orphanet. The portal for rare diseases and orphan drugs. 2023–03–20; Available from: https://www.orpha.net .
Aoki, M. & Takahashi, T. Dysferlinopathy. 2004 2021 May 27; Available from: https://www.ncbi.nlm.nih.gov/books/NBK1303/ .
Kirschner, J. & Bonnemann, C. G. The congenital and limb-girdle muscular dystrophies: Sharpening the focus, blurring the boundaries. Arch Neurol. 61, 189–99. https://doi.org/10.1001/archneur.61.2.189 (2004).
doi: 10.1001/archneur.61.2.189 pubmed: 14967765
Flachenecker, P. et al. Distal muscular dystrophy of Miyoshi type. Report of two cases and review of the literature. J. Neurol. 244, 23–9. https://doi.org/10.1007/pl00007726 (1997).
doi: 10.1007/pl00007726 pubmed: 9007741
Rosales, X. Q. et al. Novel diagnostic features of dysferlinopathies. Muscle Nerve. 42, 14–21. https://doi.org/10.1002/mus.21650 (2010).
doi: 10.1002/mus.21650 pubmed: 20544924 pmcid: 3025537
Spuler, S. et al. Dysferlin-deficient muscular dystrophy features amyloidosis. Ann. Neurol. 63, 323–8. https://doi.org/10.1002/ana.21309 (2008).
doi: 10.1002/ana.21309 pubmed: 18306167
Milone, M., Liewluck, T., Winder, T. L. & Pianosi, P. T. Amyloidosis and exercise intolerance in ANO5 muscular dystrophy. Neuromuscul. Disord. 22, 13–5. https://doi.org/10.1016/j.nmd.2011.07.005 (2012).
doi: 10.1016/j.nmd.2011.07.005 pubmed: 21820307
Liewluck, T. et al. ANO5-muscular dystrophy: Clinical, pathological and molecular findings. Eur. J. Neurol. 20, 1383–9. https://doi.org/10.1111/ene.12191 (2013).
doi: 10.1111/ene.12191 pubmed: 23663589
Cacciottolo, M. et al. Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations. Eur. J. Hum. Genet. 19, 974–80. https://doi.org/10.1038/ejhg.2011.70 (2011).
doi: 10.1038/ejhg.2011.70 pubmed: 21522182 pmcid: 3179367
Database, T. u. m. UMD-DYSF Locus Specific Database. Available from: http://www.umd.be/DYSF/ .
Bansal, D. et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 423, 168–72. https://doi.org/10.1038/nature01573 (2003).
doi: 10.1038/nature01573 pubmed: 12736685
Codding, S. J., Marty, N., Abdullah, N. & Johnson, C. P. Dysferlin Binds SNAREs (Soluble N-Ethylmaleimide-sensitive Factor (NSF) Attachment Protein Receptors) and stimulates membrane fusion in a calcium-sensitive manner. J. Biol. Chem. 291, 14575–84. https://doi.org/10.1074/jbc.M116.727016 (2016).
doi: 10.1074/jbc.M116.727016 pubmed: 27226605 pmcid: 4938179
Fujita, E. et al. Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: Ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum. Mol. Genet. 16, 618–29. https://doi.org/10.1093/hmg/ddm002 (2007).
doi: 10.1093/hmg/ddm002 pubmed: 17331981
Schoewel, V. et al. Dysferlin-peptides reallocate mutated dysferlin thereby restoring function. PLoS One. 7, e49603. https://doi.org/10.1371/journal.pone.0049603 (2012).
doi: 10.1371/journal.pone.0049603 pubmed: 23185377 pmcid: 3502493
Scott, I. L. et al. Pathogenic mutations in the C2A domain of dysferlin form amyloid that activates the inflammasome. bioRxiv https://doi.org/10.1101/2023.04.24.538129 (2023).
doi: 10.1101/2023.04.24.538129 pubmed: 38318207 pmcid: 10843151
Sula, A. et al. Crystal structures of the human Dysferlin inner DysF domain. BMC Struct. Biol. 14, 3. https://doi.org/10.1186/1472-6807-14-3 (2014).
doi: 10.1186/1472-6807-14-3 pubmed: 24438169 pmcid: 3898210
Galvin, J. E. et al. The muscle protein dysferlin accumulates in the Alzheimer brain. Acta. Neuropathol. 112, 665–71. https://doi.org/10.1007/s00401-006-0147-8 (2006).
doi: 10.1007/s00401-006-0147-8 pubmed: 17024495 pmcid: 1705477
Harris, E. et al. The clinical outcome study for dysferlinopathy: An international multicenter study. Neurol. Genet. 2, e89. https://doi.org/10.1212/NXG.0000000000000089 (2016).
doi: 10.1212/NXG.0000000000000089 pubmed: 27602406 pmcid: 4994875
Cherbuin, N. et al. Mild cognitive disorders are associated with different patterns of brain asymmetry than normal aging: The PATH through life study. Front Psychiatry. 1, 11. https://doi.org/10.3389/fpsyt.2010.00011 (2010).
doi: 10.3389/fpsyt.2010.00011 pubmed: 21423423 pmcid: 3059654
Lewis, M. M. et al. Asymmetrical lateral ventricular enlargement in Parkinson’s disease. Eur. J. Neurol. 16, 475–81. https://doi.org/10.1111/j.1468-1331.2008.02430.x (2009).
doi: 10.1111/j.1468-1331.2008.02430.x pubmed: 19187264
Li, P. et al. Hemispheric asymmetry in the human brain and in Parkinson’s disease is linked to divergent epigenetic patterns in neurons. Genome Biol. 21, 61. https://doi.org/10.1186/s13059-020-01960-1 (2020).
doi: 10.1186/s13059-020-01960-1 pubmed: 32151270 pmcid: 7063821
Lubben, N., Ensink, E., Coetzee, G. A. & Labrie, V. The enigma and implications of brain hemispheric asymmetry in neurodegenerative diseases. Brain Commun. 3, fcab211. https://doi.org/10.1093/braincomms/fcab211 (2021).
doi: 10.1093/braincomms/fcab211 pubmed: 34557668 pmcid: 8454206
Dromard, Y. et al. Dual imaging of dendritic spines and mitochondria in vivo reveals hotspots of plasticity and metabolic adaptation to stress. Neurobiol. Stress. 15, 100402. https://doi.org/10.1016/j.ynstr.2021.100402 (2021).
doi: 10.1016/j.ynstr.2021.100402 pubmed: 34611532 pmcid: 8477201
Lopez-Gambero, A. J. et al. A negative energy balance is associated with metabolic dysfunctions in the hypothalamus of a humanized preclinical model of Alzheimer’s disease, the 5XFAD mouse. Int. J. Mol. Sci. 22, 5365. https://doi.org/10.3390/ijms22105365 (2021).
doi: 10.3390/ijms22105365 pubmed: 34065168 pmcid: 8161294
Muddapu, V. R. & Chakravarthy, V. S. Influence of energy deficiency on the subcellular processes of Substantia Nigra Pars Compacta cell for understanding Parkinsonian neurodegeneration. Sci. Rep. 11, 1754. https://doi.org/10.1038/s41598-021-81185-9 (2021).
doi: 10.1038/s41598-021-81185-9 pubmed: 33462293 pmcid: 7814067
Grounds, M. D. et al. Lipid accumulation in dysferlin-deficient muscles. Am. J. Pathol. 184, 1668–1676. https://doi.org/10.1016/j.ajpath.2014.02.005 (2014).
doi: 10.1016/j.ajpath.2014.02.005 pubmed: 24685690
Alharbi, N. et al. Clinical, neurophysiological, radiological, pathological, and genetic features of dysferlinopathy in Saudi Arabia. Front Neurosci. 16, 815556. https://doi.org/10.3389/fnins.2022.815556 (2022).
doi: 10.3389/fnins.2022.815556 pubmed: 35273475 pmcid: 8902167
Bell, D. J. Asymmetry of the lateral ventricles. (2022); Available from: https://doi.org/10.53347/rID-59363 .
Fanin, M., Nascimbeni, A. C. & Angelini, C. Muscle protein analysis in the detection of heterozygotes for recessive limb girdle muscular dystrophy type 2B and 2E. Neuromuscul. Disord. 16, 792–9. https://doi.org/10.1016/j.nmd.2006.06.010 (2006).
doi: 10.1016/j.nmd.2006.06.010 pubmed: 16934466
Illa, I. et al. Symptomatic dysferlin gene mutation carriers: Characterization of two cases. Neurology. 68, 1284–1289. https://doi.org/10.1212/01.wnl.0000256768.79353.60 (2007).
doi: 10.1212/01.wnl.0000256768.79353.60 pubmed: 17287450
Jalali-Sefid-Dashti, M., Nel, M., Heckmann, J. M. & Gamieldien, J. Exome sequencing identifies novel dysferlin mutation in a family with Pauci-symptomatic heterozygous carriers. BMC Med. Genet. 19, 95. https://doi.org/10.1186/s12881-018-0613-x (2018).
doi: 10.1186/s12881-018-0613-x pubmed: 29879922 pmcid: 5992709
Aso, M. et al. Asymmetry of the ventricle and age at the onset of schizophrenia. Eur Arch. Psychiatry Clin. Neurosci. 245, 142–144. https://doi.org/10.1007/BF02193086 (1995).
doi: 10.1007/BF02193086 pubmed: 7669820
Bartos, A., Gregus, D., Ibrahim, I. & Tintera, J. Brain volumes and their ratios in Alzheimer s disease on magnetic resonance imaging segmented using Freesurfer 6.0. Psychiatry Res. Neuroimaging. 287, 70–74. https://doi.org/10.1016/j.pscychresns.2019.01.014 (2019).
doi: 10.1016/j.pscychresns.2019.01.014 pubmed: 31003044
Grosman, H. et al. Computed tomography and lateral ventricular asymmetry: Clinical and brain structural correlates. Can. Assoc. Radiol. J. 41, 342–346 (1990).
pubmed: 2257506
Kiroglu, Y. et al. Cerebral lateral ventricular asymmetry on CT: How much asymmetry is representing pathology?. Surg. Radiol. Anat. 30, 249–55. https://doi.org/10.1007/s00276-008-0314-9 (2008).
doi: 10.1007/s00276-008-0314-9 pubmed: 18253688
Kong, X. Z. et al. Mapping brain asymmetry in health and disease through the ENIGMA consortium. Hum. Brain Mapp. 43, 167–181. https://doi.org/10.1002/hbm.25033 (2022).
doi: 10.1002/hbm.25033 pubmed: 32420672
Min, J. et al. Diagnostic efficacy of structural MRI in patients with mild-to-moderate Alzheimer disease: Automated volumetric assessment versus visual assessment. AJR Am. J. Roentgenol. 208, 617–623. https://doi.org/10.2214/AJR.16.16894 (2017).
doi: 10.2214/AJR.16.16894 pubmed: 28075620
Kolisek, M. et al. Magnesium extravaganza: A critical compendium of current research into cellular Mg
doi: 10.1007/112_2018_15 pubmed: 30406297
Kolisek, M. et al. Mrs2p is an essential component of the major electrophoretic Mg
doi: 10.1093/emboj/cdg122 pubmed: 12628916 pmcid: 151051
Mathew, A. A. & Panonnummal, R. ’Magnesium’-the master cation-as a drug-possibilities and evidences. Biometals. 34, 955–986. https://doi.org/10.1007/s10534-021-00328-7 (2021).
doi: 10.1007/s10534-021-00328-7 pubmed: 34213669 pmcid: 8249833
Yamanaka, R. et al. Mitochondrial Mg
doi: 10.1038/srep30027 pubmed: 27458051 pmcid: 4960558
Rosanoff, A. et al. Recommendation on an updated standardization of serum magnesium reference ranges. Eur. J. Nutr. 61, 3697–3706. https://doi.org/10.1007/s00394-022-02916-w (2022).
doi: 10.1007/s00394-022-02916-w pubmed: 35689124 pmcid: 9186275
Al Shammaa, A. et al. Serum magnesium is inversely Associated with body composition and metabolic syndrome. Diabetes Metab. Syndr. Obes. 16, 95–104. https://doi.org/10.2147/DMSO.S391369 (2023).
doi: 10.2147/DMSO.S391369 pubmed: 36760601 pmcid: 9844104
Ilincic, B. & Oluski, D. Association between body composition and magnesium level in midlle aged women: PS073. Porto. Biomed. J. 2, 177–178. https://doi.org/10.1016/j.pbj.2017.07.008 (2017).
doi: 10.1016/j.pbj.2017.07.008 pubmed: 32258619 pmcid: 6806906
Shamnani, G. et al. Serum magnesium in relation with obesity. Natl. J. Physiol. Pharm. Pharmacol. 8, 1074–1077. https://doi.org/10.5455/njppp.2018.8.0104016022018 (2018).
doi: 10.5455/njppp.2018.8.0104016022018
Van Eyck, A. et al. Body composition helps to elucidate the different origins of low serum magnesium in children with obesity compared to children with type 1 diabetes. Eur. J. Pediatr. 182, 3743–3753. https://doi.org/10.1007/s00431-023-05046-5 (2023).
doi: 10.1007/s00431-023-05046-5 pubmed: 37289233
Vink, R. & Nechifor, M. Magnesium in the central nervous system (University of Adelaide Press, 2011).
doi: 10.1017/UPO9780987073051
Andrasi, E., Igaz, S., Molnar, Z. & Mako, S. Disturbances of magnesium concentrations in various brain areas in Alzheimer’s disease. Magnes. Res. 13, 189–196 (2000).
pubmed: 11008926
Barbiroli, B. et al. Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson’s disease. Mov. Disord. 14, 430–5. https://doi.org/10.1002/1531-8257(199905)14:3%3c430::aid-mds1007%3e3.0.co;2-s (1999).
doi: 10.1002/1531-8257(199905)14:3<430::aid-mds1007>3.0.co;2-s pubmed: 10348465
Lo, K. et al. Relations of magnesium intake to cognitive impairment and dementia among participants in the Women’s health initiative memory study: A prospective cohort study. BMJ Open. 9, e030052. https://doi.org/10.1136/bmjopen-2019-030052 (2019).
doi: 10.1136/bmjopen-2019-030052 pubmed: 31685499 pmcid: 6858129
Maier, J. A. M. et al. Magnesium and the brain: A focus on neuroinflammation and neurodegeneration. Int. J. Mol. Sci. 24, 223. https://doi.org/10.3390/ijms24010223 (2022).
doi: 10.3390/ijms24010223 pubmed: 36613667 pmcid: 9820677
Nadler, J. L. et al. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension. 21, 1024–9. https://doi.org/10.1161/01.hyp.21.6.1024 (1993).
doi: 10.1161/01.hyp.21.6.1024 pubmed: 8505087
Yasui, M., Kihira, T. & Ota, K. Calcium, magnesium and aluminum concentrations in Parkinson’s disease. Neurotoxicology. 13, 593–600 (1992).
pubmed: 1475063
Li, W. et al. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model. Mol. Brain. 7, 65. https://doi.org/10.1186/s13041-014-0065-y (2014).
doi: 10.1186/s13041-014-0065-y pubmed: 25213836 pmcid: 4172865
Serita, T. et al. Dietary magnesium deficiency impairs hippocampus-dependent memories without changes in the spine density and morphology of hippocampal neurons in mice. Brain Res. Bull. 144, 149–157. https://doi.org/10.1016/j.brainresbull.2018.11.019 (2019).
doi: 10.1016/j.brainresbull.2018.11.019 pubmed: 30500564
Xu, Z. P. et al. Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer’s model. PLoS One. 9, e108645. https://doi.org/10.1371/journal.pone.0108645 (2014).
doi: 10.1371/journal.pone.0108645 pubmed: 25268773 pmcid: 4182554
Kirkland, A. E., Sarlo, G. L. & Holton, K. F. The role of magnesium in neurological disorders. Nutrients. 10, 730. https://doi.org/10.3390/nu10060730 (2018).
doi: 10.3390/nu10060730 pubmed: 29882776 pmcid: 6024559
Cherbuin, N., Kumar, R., Sachdev, P. S. & Anstey, K. J. Dietary mineral intake and risk of mild cognitive impairment: The PATH through life project. Front. Aging Neurosci. 6, 4. https://doi.org/10.3389/fnagi.2014.00004 (2014).
doi: 10.3389/fnagi.2014.00004 pubmed: 24550825 pmcid: 3912433
Ozawa, M. et al. Self-reported dietary intake of potassium, calcium, and magnesium and risk of dementia in the Japanese: The Hisayama Study. J. Am. Geriatr. Soc. 60, 1515–20. https://doi.org/10.1111/j.1532-5415.2012.04061.x (2012).
doi: 10.1111/j.1532-5415.2012.04061.x pubmed: 22860881
Haszto, C. S., Stanley, J. A., Iyengar, S. & Prasad, K. M. Regionally distinct alterations in membrane phospholipid metabolism in schizophrenia: A meta-analysis of phosphorus magnetic resonance spectroscopy studies. Biol. Psychiatry Cogn. Neurosci. Neuroimaging. 5, 264–280. https://doi.org/10.1016/j.bpsc.2019.09.008 (2020).
doi: 10.1016/j.bpsc.2019.09.008 pubmed: 31748123
Jett, S. et al. Systematic review of
doi: 10.3389/fnagi.2023.1183228 pubmed: 37273652 pmcid: 10232902
Rijpma, A. et al. Altered brain high-energy phosphate metabolism in mild Alzheimer’s disease: A 3-dimensional
doi: 10.1016/j.nicl.2018.01.031 pubmed: 29876246 pmcid: 5987799
Mandal, P. K., Akolkar, H. & Tripathi, M. Mapping of hippocampal pH and neurochemicals from in vivo multi-voxel
doi: 10.3233/JAD-2012-120166 pubmed: 22426021
Mecheri, G. et al. In vivo hippocampal
doi: 10.1016/S0924-9338(97)80203-9 pubmed: 19698521
Guillevin, C. et al. 1H–31P magnetic resonance spectroscopy: Effect of biotin in multiple sclerosis. Ann. Clin. Transl. Neurol. 6, 1332–1337. https://doi.org/10.1002/acn3.50825 (2019).
doi: 10.1002/acn3.50825 pubmed: 31353859 pmcid: 6649368
Hnilicova, P. et al. Current methods of magnetic resonance for noninvasive assessment of molecular aspects of pathoetiology in multiple sclerosis. Int. J. Mol. Sci. 21, 6117. https://doi.org/10.3390/ijms21176117 (2020).
doi: 10.3390/ijms21176117 pubmed: 32854318 pmcid: 7504207
Ren, J.
D’Rozario, A. L. et al. Brain bioenergetics during resting wakefulness are related to neurobehavioral deficits in severe obstructive sleep apnea: A
doi: 10.1093/sleep/zsy117
From, A. H. & Ugurbil, K. Standard magnetic resonance-based measurements of the Pi–>ATP rate do not index the rate of oxidative phosphorylation in cardiac and skeletal muscles. Am. J. Physiol. Cell. Physiol. 301, C1-11. https://doi.org/10.1152/ajpcell.00345.2010 (2011).
doi: 10.1152/ajpcell.00345.2010 pubmed: 21368294 pmcid: 3129822
Rietzler, A. et al. Energy metabolism measured by
doi: 10.1016/j.neurad.2021.11.006 pubmed: 34871672
Du, F. et al. Efficient in vivo
doi: 10.1002/mrm.21107 pubmed: 17191226
Kolkovsky, A. L. L.,
Council, M. R., Aids to Examination of the Peripheral Nervous System, In Memorandum No. 45., L. Her Majesty’s Stationary Office, Editor. 1976, Her Majesty’s Stationary Office: London.
Université catholique de Louvain & Hainaut, H. E. L. e. ACTIVLIM-NMD, A measure of Activity limitation for Neuromuscular disorders. (1990); Available from: https://www.rehab-scales.org/scale/activlim .
Hajdúk, M. et al. NEUROPSY štandardizácia neuropsychologickej testovej batérie na dospelej slovenskej populácii (Univerzita Komenského v Bratislave, 2021).
den Dunnen, J. T. et al. HGVS recommendations for the description of sequence variants: 2016 Update. Hum Mutat. 37, 564–569. https://doi.org/10.1002/humu.22981 (2016).
doi: 10.1002/humu.22981
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. Genet. Med. 17, 405–24. https://doi.org/10.1038/gim.2015.30 (2015).
doi: 10.1038/gim.2015.30 pubmed: 25741868 pmcid: 4544753
Lin, A. et al. Minimum reporting standards for in vivo magnetic resonance spectroscopy (MRSinMRS): Experts’ consensus recommendations. NMR Biomed. 34, e4484. https://doi.org/10.1002/nbm.4484 (2021).
doi: 10.1002/nbm.4484 pubmed: 33559967 pmcid: 8647919
Peter, S. B. & Nandhan, V. R.
doi: 10.1055/s-0041-1741090 pubmed: 35136499
Galijasevic, M. et al. Phosphorous magnetic resonance spectroscopy and molecular markers in IDH1 wild type glioblastoma. Cancers (Basel). 13, 3569. https://doi.org/10.3390/cancers13143569 (2021).
doi: 10.3390/cancers13143569 pubmed: 34298788 pmcid: 8305039
Iotti, S. et al. In vivo assessment of free magnesium concentration in human brain by 31P MRS. A new calibration curve based on a mathematical algorithm. NMR Biomed. 9, 24–32. https://doi.org/10.1002/(SICI)1099-1492(199602)9:1%3c24::AID-NBM392%3e3.0.CO;2-B (1996).
doi: 10.1002/(SICI)1099-1492(199602)9:1<24::AID-NBM392>3.0.CO;2-B pubmed: 8842030
Datta, D., blandr: a Bland-Altman Method Comparison package for R. Zenodo. (2017).
Hothorn, T., Bretz, F. & Westfall, P. Simultaneous inference in general parametric models. Biom J. 50, 346–63. https://doi.org/10.1002/bimj.200810425 (2008).
doi: 10.1002/bimj.200810425 pubmed: 18481363
Ishwaran, H. & Kogalur, U. B., Fast Unified Random Forests for Survival, Regression, and Classification (RF-SRC), R package version 3.1.1. (2022).
Lenth, R. V., emmeans: Estimated Marginal Means, aka Least-Squares Means. R package version 1.7.5. . (2022).
Maechler, M. et al., robustbase: Basic Robust Statistics R package version 0.93–7. (2021).
Pinheiro J et al., nlme: Linear and nonlinear mixed effects models. (2021). p. 1–152.
Team, R. C. R: A language and environment for statistical computing. (2021); Available from: https://www.R-project.org/ .
Hnilicova, P. et al. Dysferlinopathy manifesting with volumetric asymmetry of the inferior lateral ventricles, altered
doi: 10.17632/622xynmzr2.1

Auteurs

Petra Hnilicova (P)

Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, Mala Hora 4D, 03601, Martin, Slovakia.

Marian Grendar (M)

Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, Mala Hora 4D, 03601, Martin, Slovakia.

Monika Turcanova Koprusakova (M)

Clinic of Neurology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 03601, Martin, Slovakia.

Alzbeta Trancikova Kralova (A)

Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, Mala Hora 4D, 03601, Martin, Slovakia.

Jana Harsanyiova (J)

Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, Mala Hora 4D, 03601, Martin, Slovakia.

Martin Krssak (M)

Department of Biomedical Imaging and Image-Guided Therapy, High-Field MR Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Ivica Just (I)

Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Nadezda Misovicova (N)

M-Genetik s.r.o., P. Mudrona 504/7, 03601, Martin, Slovakia.

Martina Hikkelova (M)

Progenet s.r.o., Strecnianska 13, 85105, Bratislava, Slovakia.

Jan Grossmann (J)

Clinic of Neurology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 03601, Martin, Slovakia.

Peter Spalek (P)

Center for Neuromuscular Disease, Clinic of Neurology, University Hospital Bratislava, Slovak Medical University in Bratislava, Pazitkova 4, 83303, Bratislava, Slovakia.

Iveta Meciarova (I)

Department of Pathology, Unilabs Slovensko Patologia s.r.o., Ruzinovska 6, 82606, Bratislava, Slovakia.

Egon Kurca (E)

Clinic of Neurology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 03601, Martin, Slovakia.

Norbert Zilka (N)

Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska Cesta 5779/9, 84510, Bratislava, Slovakia.

Kamil Zelenak (K)

Clinic of Radiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 03601, Martin, Slovakia.

Wolfgang Bogner (W)

Department of Biomedical Imaging and Image-Guided Therapy, High-Field MR Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Martin Kolisek (M)

Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, Mala Hora 4D, 03601, Martin, Slovakia. martin.kolisek@uniba.sk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH